- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03455699
VeClose Five Year Follow-Up Extension Study
10 de abril de 2019 actualizado por: Medtronic Endovascular
Follow-up of Patients Treated in VeClose Study (Five Years)
The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).
Descripción general del estudio
Estado
Terminado
Descripción detallada
The VeClose Five Year Follow-up Extension Study will continue to assess the safety and efficacy of the VenaSeal Closure System for the long term effect on closure of the great saphenous vein by conducting a follow-up visit at five years post index procedure/enrollment in the VeClose study.
Tipo de estudio
De observación
Inscripción (Actual)
114
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85255
- Morrison Vein Institute
-
-
California
-
San Diego, California, Estados Unidos, 92121
- GBK Cosmetic Laser Dermatology
-
-
Colorado
-
Greenwood Village, Colorado, Estados Unidos, 80111
- Radiology Imaging Associates (RIA)
-
-
Illinois
-
Springfield, Illinois, Estados Unidos, 62701
- Prairie Education & Research Cooperative
-
-
Maryland
-
Hunt Valley, Maryland, Estados Unidos, 21030
- MD Laser Skin & Vein Institute
-
-
New York
-
North Tonawanda, New York, Estados Unidos, 14120
- Vein Institute of Buffalo
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Inovia Vein Speciality Center
-
-
Virginia
-
Virginia Beach, Virginia, Estados Unidos, 23452
- Sentara Vascular Specialists
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98004
- Lake Washington Vascular
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
21 años a 70 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Subjects currently enrolled in both arms of the VeClose Study (NCT01807585) will be assessed for eligibility to enroll in the VeClose Five Year Follow-up Extension Study.
All subjects must meet the inclusion criteria and must not meet the exclusion criteria.
Assessment of eligibility is based on data available to the investigator at the time of subject enrollment.
The subject will be considered to be enrolled in the VeClose Five Year Follow-up Extension Study after the informed consent is signed/dated and all of the study eligibility criteria have been met.
Descripción
Inclusion Criteria:
- Enrolled in the VeClose study.
- Able and willing to complete the required 5 year study visit including Duplex ultrasound exam.
- Able and willing to provide written informed consent prior to study specific data collection.
Exclusion Criteria:
1. Withdrew consent from the VeClose study.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Experimental: VenaSeal SCS
Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV).
The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
|
Procedimiento no tumescente, no térmico, no esclerosante que utiliza un adhesivo médico patentado que se administra por vía endovenosa para cerrar la vena.
Otros nombres:
|
|
Active Comparator: RFA
Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV).
Heat is applied to the target vein using radiofrequency energy to ablate the target vein.
Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
|
Ablación térmica por radiofrecuencia de la GSV mediante el sistema Covidien ClosureFast.
Otros nombres:
|
|
Experimental: Roll-in (VenaSeal SCS)
Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV).
The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
|
Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Complete Closure of the Target Vein at 5 years after index treatment in the VeClose study (NCT01807585).
Periodo de tiempo: 5 years
|
Complete closure is defined as Doppler ultrasound examination showing closure along entire treated target vein segment with no discrete segments of patency exceeding 5cm.
|
5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Venous Clinical Severity Score (VCSS)
Periodo de tiempo: 5 years
|
Change in Venous Clinical Severity Score (VCSS) at 5 years as compared to baseline data from the VeClose study (NCT01807585).
The VCSS is an Investigator assessment of the severity of venous reflux disease, assessing signs and symptoms such as pain, varicose veins, venous edema, skin pigmentation, induration and inflammation.
The VCSS score is the sum of responses to 10 questions.
Each question has a total possible of 3 points, which are then added for each question.
The overall VCSS scores can therefore range from 0 (no venous disease) to 30 (severe venous disease).
High scores indicate worse outcomes and "0" is the best possible outcome.
|
5 years
|
|
Aberdeen Varicose Vein Questionnaire (AVVQ)
Periodo de tiempo: 5 years
|
Change in Aberdeen Varicose Vein Questionnaire (AVVQ) at 5 years as compared to baseline data from the VeClose study (NCT01807585).
AVVQ is a disease-specific 13-item questionnaire used to assess the impact of varicose veins on the quality of life, such as pain caused by varicose veins, and need to take painkilling tablets for varicose veins as well as assessing the presence of signs/symptoms such as ankle swelling, purple discoloration and rash/eczema.
The total score of AVVQ is the sum of all questions for each leg.
Scores range from 0 (no disease) to 100 (maximal disease).
High scores indicate worse outcomes and "0" is the best possible outcome.
|
5 years
|
|
Quality of Life survey (EQ-5D)
Periodo de tiempo: 5 years
|
Change in Quality of Life survey (EQ-5D) at 5 years as compared to baseline data from the VeClose study (NCT01807585).
EQ-5D is a short generic quality of life survey that is commonly used outside of the United States for health technology assessments.
The "health state today" question provides an overall assessment along a 20-cm visual analog scale (VAS) with a range from 0 ("worst imaginable health state") to 100 ("best imaginable health state").
|
5 years
|
|
CEAP classification ("clinical, etiology, assessment and pathophysiology")
Periodo de tiempo: 5 years
|
Standardized measure of the degree of venous insufficiency and secondary manifestations of venous disease as measured by the treating physician.
|
5 years
|
|
Satisfaction with Treatment
Periodo de tiempo: 5 years
|
Satisfaction with Treatment assessment consists of a brief 2-question patient survey rating satisfaction with treatment provided and whether the subject would undergo the assigned treatment again.
The number (percent) of subjects on each level of satisfaction are summarized (Very satisfied, Somewhat satisfied, Somewhat dissatisfied, Very dissatisfied).
The number (percent) of subjects for the second satisfaction question, "would undergo treatment again" were also summarized by response (Definitely have again, Might have again, Not have again).
|
5 years
|
|
Adverse events (AE) related to the target GSV
Periodo de tiempo: 5 years
|
AEs related to the GSV will be tabulated and reporting using the MedDRA dictionary, version 16.1.
|
5 years
|
|
Adjunctive procedures performed on the study limb
Periodo de tiempo: 5 years
|
Details of adjunctive procedures performed on the study limb will be captured on Case Report Forms (CRFs)
|
5 years
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Nick Morrison, MD, Morrison Vein Institute
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Morrison N, Gibson K, Vasquez M, Weiss R, Cher D, Madsen M, Jones A. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):321-330. doi: 10.1016/j.jvsv.2016.12.005. Epub 2017 Mar 6.
- Kolluri R, Gibson K, Cher D, Madsen M, Weiss R, Morrison N. Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2016 Oct;4(4):407-15. doi: 10.1016/j.jvsv.2016.06.017. Epub 2016 Aug 8.
- Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):978-989. doi: 10.1016/j.jvsv.2019.12.080. Epub 2020 Mar 20.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de julio de 2016
Finalización primaria (Actual)
1 de enero de 2019
Finalización del estudio (Actual)
1 de enero de 2019
Fechas de registro del estudio
Enviado por primera vez
28 de febrero de 2018
Primero enviado que cumplió con los criterios de control de calidad
28 de febrero de 2018
Publicado por primera vez (Actual)
6 de marzo de 2018
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
12 de abril de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
10 de abril de 2019
Última verificación
1 de abril de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CP-1011
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre VenaSeal SCS
-
Medtronic EndovascularSapheon, Inc.TerminadoGran vena safena (GSV) con enfermedad por reflujo venosoEstados Unidos
-
Lake Washington VascularSyntactxTerminadoReflujo venosoEstados Unidos
-
Universitair Ziekenhuis Brusselthe eNose companyTerminadoSíndrome de cirugía de espalda fallidaBélgica
-
Moens MaartenTerminadoSíndrome de cirugía de espalda fallidaBélgica
-
University Hospital TuebingenAbbottTerminadoEstimulación de la médula espinal (SCS) | Metabolismo de la glucosa en sangre | Pinza hiperinsulinémica euglucémicaAlemania
-
Meshalkin Research Institute of Pathology of CirculationTerminadoIsquemia crónica que amenaza las extremidadesFederación Rusa
-
University of MichiganNational Institute of Mental Health (NIMH)Terminado
-
Universitair Ziekenhuis BrusselTerminadoSíndrome de cirugía de espalda fallidaBélgica
-
Stimgenics LLCTerminado
-
Stimgenics LLCTerminadoDolor lumbar crónicoEstados Unidos